EUVIMEDEUVIMED entdecken
Crossref

Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals

Mariateresa Buongiorno iD, Gonzalo Sánchez-Benavides, Clara Marzal-Espí, Darly Milena Giraldo, Jerzy Krupinski, Natalia Cullell, Oriol Grau-Rivera, Marc Suárez-Calvet, Juan Domingo Gispert, Alex de la Sierra, Alzheimer's Disease Neuroimaging Initiative **, and the European Prevention of Alzheimer's Disease (EPAD) Consortium

Journal of Alzheimer’s Disease · 2024

DOI: 10.1177/13872877241293812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Mariateresa Buongiorno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Blood-Brain Barrier, Biomarkers, Amyloid beta-Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Innovative Medicines Initiative, Alzheimer's Association, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD pathophysiological markers is unknown. We compared cerebrospinal fluid (CSF) AD biomarker levels among non-demented individuals taking low, intermediate, or high BBB permeable β-blockers in two samples (ADNI: n = 216; EPAD: n = 79). We found that CSF amyloid-β levels were higher in individuals taking highly permeable β-blockers in the ADNI sample. This result was not replicated in EPAD, in which diminished levels of pTau181 and tTau were observed. These data suggest that β-blockers may impact AD pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBlood-Brain BarrierBiomarkersAmyloid beta-PeptidesAdrenergic beta-Antagoniststau ProteinsHumansFemaleAgedMalePeptide FragmentsAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid-βbeta-blockersblood-brain barriercerebrospinal fluid biomarkerstau

Substanzen

BiomarkersAmyloid beta-PeptidesAdrenergic beta-Antagoniststau ProteinsPeptide Fragments

Autor:innen und Institutionen

  • Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Neurovascular Diseases Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
  • Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Hospital del Mar Research Institute, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
  • Department of Neurology, Fundació Assistencial Mútua Terrassa, Terrassa, Spain.

ORCID-Profile: Mariateresa Buongiorno

Förderung

  • Innovative Medicines Initiative
  • Alzheimer's Association
  • Instituto de Salud Carlos III
  • National Institute on Aging

Zitieren

APA

Buongiorno, M., Sánchez-Benavides, G., Marzal-Espí, C., Giraldo, D. M., Krupinski, J., Cullell, N., Grau-Rivera, O., Suárez-Calvet, M., Gispert, J. D., de la Sierra, A., Alzheimer's Disease Neuroimaging Initiative **, & and the European Prevention of Alzheimer's Disease (EPAD) Consortium (2024). Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241293812

Vancouver

Buongiorno M, Sánchez-Benavides G, Marzal-Espí C, Giraldo DM, Krupinski J, Cullell N, et al. Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241293812

BibTeX
@article{Buongiorno2024,
  author = {Buongiorno, Mariateresa and Sánchez-Benavides, Gonzalo and Marzal-Espí, Clara and Giraldo, Darly Milena and Krupinski, Jerzy and Cullell, Natalia and Grau-Rivera, Oriol and Suárez-Calvet, Marc and Gispert, Juan Domingo and de la Sierra, Alex and Alzheimer's Disease Neuroimaging Initiative **, Alzheimer's Disease Neuroimaging Initiative ** and and the European Prevention of Alzheimer's Disease (EPAD) Consortium, and the European Prevention of Alzheimer's Disease (EPAD) Consortium},
  title = {Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.1177/13872877241293812}
}
Kostenlos starten →